[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572113":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":30,"centralContacts":37,"locations":43,"responsibleParty":56,"collaborators":30,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":30,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":30,"studyType":73,"phases":74,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":30,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group C","PLACEBO_COMPARATOR","patients will receive placebo (normal saline)",[13],"Drug: normal Saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Group N","ACTIVE_COMPARATOR","patients will receive neostigmine (40 μg\u002Fkg) plus atropine (20 μg\u002Fkg)",[19],"Drug: Neostigmine",{"label":21,"type":16,"description":22,"interventionNames":23},"Group K","patients will receive ketorolac (0.5 mg\u002Fkg)",[24],"Drug: Ketorolac",[26,31,34],{"type":27,"name":28,"description":11,"armGroupLabels":29,"otherNames":30},"DRUG","normal Saline",[9],null,{"type":27,"name":32,"description":17,"armGroupLabels":33,"otherNames":30},"Neostigmine",[15],{"type":27,"name":35,"description":22,"armGroupLabels":36,"otherNames":30},"Ketorolac",[21],[38],{"name":39,"role":40,"phone":41,"phoneExt":30,"email":42},"Ghada Abo Elfadl, MD","CONTACT","01005802086","ghadafadl77@gmail.com",[44],{"facility":45,"status":30,"city":46,"state":30,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":30},"Faculty of medicine, Assiut University, Assiut, Egypt,","Asyut","71515","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.18368,27.18096,{"lat":54,"lon":53},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Ghada Mohammed AboelFadl","Principal investigator","100572113","phase-1-prophylactic-intravenous-injection-of-neostigmine-plus-atropine-versus-ketorolac-on-post-dural-puncture-headache-in-patients-undergoing-infraumbilical-surgeries-100572113",false,"NCT06729047","Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries","Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries: A Randomized Clinical Trial","Inclusion Criteria:\n\n* BMI less than 35 kg\u002Fm2\n* Scheduled for infraumbilical surgeries\n* American Society of Anesthesiologists (ASA) physical status: I and II\n\nExclusion Criteria:\n\n1. ASA physical status more than II.\n2. History of allrgic response to local anaesthetics or any of the medications used in the study\n3. Patients with cognitive impairment\n4. pregnancy\n5. Basal body temperature of more than 38°C or less than 36°C\n6. BMI more than 35 kg\u002Fm2","ALL","18 Years","65 Years",{"count":71,"type":72},330,"ESTIMATED","INTERVENTIONAL",[75,76],"PHASE1","PHASE2","Post-dural puncture headache (PDPH) or spinal (or post-spinal) headache is one of the most common side effects of spinal anesthesia, with an incidence of 6-36%. The incidence of this complication was reported to be 76-85% after accidental dural puncture in epidural anesthesia. It usually starts within several hours after spinal anesthesia, but sometimes it can be delayed for up to 2 weeks, which usually resolves within a few days",[79],"Post-Dural Puncture Headache",[32,81],"ketorolac","NOT_YET_RECRUITING","2024-12-08",{"date":85,"type":86},"2024-12-11","ACTUAL",{"date":88,"type":72},"2024-12-15",{"date":90,"type":72},"2025-11-05",{"name":5,"class":6},1]